CARISMA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.64 USD | 0.00% |
|
+0.61% | -44.03% |
| 04-11 | BTIG Starts Carisma Therapeutics With Buy Rating, $6 Price Target | MT |
| 04-02 | HC Wainwright Adjusts Price Target on Carisma Therapeutics to $9 From $11, Maintains Buy Rating | MT |
| Sales 2024 * | 16.93M 23.14M | Sales 2025 * | 13.83M 18.91M | Capitalization | 68.13M 93.13M |
|---|---|---|---|---|---|
| Net income 2024 * | -58M -79.28M | Net income 2025 * | -69M -94.32M | EV / Sales 2024 * | 4.02 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 4.93 x |
| P/E ratio 2024 * |
-1.27
x | P/E ratio 2025 * |
-1.23
x | Employees | 107 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 67.27% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 week | +0.61% | ||
| Current month | -27.75% | ||
| 1 month | -26.79% | ||
| 3 months | -23.72% | ||
| 6 months | -40.36% | ||
| Current year | -44.03% |
1 week
1.60
1.91
1 month
1.532.30
Current year
1.533.06
1 year
1.539.77
3 years
1.539.77
5 years
1.539.77
10 years
1.539.77
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 34 | 15-12-31 | |
Steven Kelly
CEO | Chief Executive Officer | 59 | 18-01-31 |
Richard Morris
DFI | Director of Finance/CFO | 51 | 21-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Steven Kelly
CEO | Chief Executive Officer | 59 | 18-01-31 |
Sanford Zweifach
CHM | Chairman | 68 | 21-10-31 |
| Director/Board Member | 66 | 22-01-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - | |
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 1.64 | 0.00% | 54,732 |
| 24-04-25 | 1.64 | -2.38% | 112,570 |
| 24-04-24 | 1.68 | -1.18% | 50,919 |
| 24-04-23 | 1.7 | -9.09% | 135,661 |
| 24-04-22 | 1.87 | +14.72% | 144,126 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm
More quotes
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the treatment of solid tumors. Its first product candidate, CT-0508, is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Its second product candidate, CT-0525, is an ex vivo gene-modified autologous chimeric antigen receptor-macrophage (CAR-Macrophage) cellular therapy intended to treat solid tumors that overexpress HER2. CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.64
USD
Average target price
8.4
USD
Spread / Average Target
+412.20%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -44.03% | 68.13M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- CARM Stock
